RECRUITING

Regional Lipolysis and Adipocyte Lipolysis Protein Stimulation

Talk to us

Conditions

Obesity

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Adults who gain most of their excess weight in the abdominal area typically do not respond to factors that "turn on" fat cells the same way as people who don't have excessive weight. Researchers are trying to understand why fat tissue responds differently in people with different body types.

Official Title

Stimulation of Regional Lipolysis and Adipocyte Lipolysis Proteins

Quick Facts

Study Start:2024-10-01
Study Completion:2027-04-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT06416969

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years to 65 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:Yes
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Males and females between 18 and 65 years of age who are able to comprehend instructions, follow study procedures, willing to sign an informed consent form, and consume an isoenergetic diet eating all meals from Mayo Clinical Research and Trials Unit for at least 3 days prior to study.
  2. * Overweight/Obese volunteers will have a BMI 29.0 - 40.0 kg/m2
  3. * Female subjects are eligible if they meet the following criteria:
  4. * Are not pregnant or nursing
  5. * All women of childbearing potential will have a negative urine pregnancy test at screening and a negative urine pregnancy test within 48 hours before administering study drug.
  6. * Recent or current research participation in a study that involves an investigational drug. Participants in other clinical trials that involve an investigational drug will not be able to participate in this study until 12 weeks after their participation in the other study is complete or \> than five half-lives of the compound, whichever is longer. If Yes look at consent form and f/u visits:
  7. * Current use of medications that alter fatty acid or adipose metabolism possibly given: if yes, exclude
  8. * Amount of blood drawn during the study (if our study plus this one draw ≥ 450 ml these should be separated by 8 weeks
  9. * Previous labs:
  10. * Fasting glucose \< 126 mg/dl for non-diabetic UBO
  11. * Hb ≥ 11.0 for women and ≥ 12 for men
  12. * platelets \> 100 000
  1. * Individuals with a history of a disease process such as:
  2. * Ischemic heart disease
  3. * Atherosclerotic valvular disease
  4. * Persistent blood pressure greater than 160/95 despite antihypertensive medication
  5. * Peripheral artery disease
  6. * Any history of trans-ischemic attacks.
  7. * Coronary artery disease.
  8. * Liver cirrhosis
  9. * Significant renal impairment as documented in medical chart.
  10. * Smokers
  11. * Diagnosis of Diabetes Mellitus.
  12. * Concomitant use of medications that can alter free fatty acid metabolism or pose a drug-drug interaction: statins (if yes hold for 4 weeks and receive primary care provider's approval); Niacin; Fibrates; thiazolidinedione; Beta-blockers; Oral or injected corticosteroids or anabolic steroids; Linezolid; Dihydroergotamine; Phenelzine; daily phosphodiesterase inhibitors
  13. * Allergy to lidocaine
  14. * Allergy to indocyanine green.

Contacts and Locations

Study Contact

Pamela Reich
CONTACT
(507) 255-6062
reich.pamela@mayo.edu
Kelli Lytle, PhD
CONTACT
(507) 255-1488
lytle.kelli@mayo.edu

Principal Investigator

Michael Jensen, MD
PRINCIPAL_INVESTIGATOR
Mayo Clinic

Study Locations (Sites)

Mayo Clinic in Rochester
Rochester, Minnesota, 55905
United States

Collaborators and Investigators

Sponsor: Mayo Clinic

  • Michael Jensen, MD, PRINCIPAL_INVESTIGATOR, Mayo Clinic

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2024-10-01
Study Completion Date2027-04-01

Study Record Updates

Study Start Date2024-10-01
Study Completion Date2027-04-01

Terms related to this study

Additional Relevant MeSH Terms

  • Obesity